12,174 Shares in SI-BONE, Inc. (NASDAQ:SIBN) Purchased by EntryPoint Capital LLC

EntryPoint Capital LLC bought a new stake in shares of SI-BONE, Inc. (NASDAQ:SIBN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,174 shares of the company’s stock, valued at approximately $171,000.

Several other large investors have also recently made changes to their positions in the business. FMR LLC increased its position in SI-BONE by 103.6% during the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after buying an additional 1,198 shares in the last quarter. Mainstream Capital Management LLC bought a new position in shares of SI-BONE during the fourth quarter valued at $53,000. R Squared Ltd purchased a new position in shares of SI-BONE in the 4th quarter worth about $73,000. KLP Kapitalforvaltning AS bought a new position in SI-BONE in the 4th quarter worth about $97,000. Finally, Walleye Capital LLC purchased a new stake in SI-BONE during the 3rd quarter valued at about $144,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SI-BONE Stock Up 0.4 %

SIBN opened at $14.04 on Friday. The stock has a market capitalization of $596.04 million, a price-to-earnings ratio of -15.26 and a beta of 1.17. The firm has a 50 day moving average price of $16.41 and a 200-day moving average price of $14.77. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $19.16. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last announced its earnings results on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The business had revenue of $49.00 million during the quarter, compared to analyst estimates of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Equities research analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SIBN. Truist Financial reiterated a “buy” rating and issued a $22.00 target price (up previously from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Needham & Company LLC increased their target price on SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, SI-BONE currently has an average rating of “Buy” and a consensus price target of $24.40.

Insider Buying and Selling at SI-BONE

In other news, CFO Anshul Maheshwari sold 5,304 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total transaction of $73,778.64. Following the completion of the sale, the chief financial officer now owns 189,319 shares of the company’s stock, valued at $2,633,427.29. This represents a 2.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Anthony J. Recupero sold 3,670 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total transaction of $51,013.00. Following the completion of the transaction, the insider now owns 222,814 shares in the company, valued at $3,097,114.60. This trade represents a 1.62 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,311 shares of company stock valued at $130,356. 3.90% of the stock is owned by company insiders.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.